Filing Flows › Altimmune (ALT) › Q3 2025 › vs Q2 2025
Altimmune (ALT) Q3 2025 vs Q2 2025 (quarter over quarter)
Altimmune's revenue rose $0 (0%) from $5K in Q2 2025 to $5K in Q3 2025.
Altimmune, Q3 2025: revenue $5K (0% year over year), net loss $19.0M, operating cash flow −$11.9M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q3 2025 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $5K | $5K | $0 | 0% |
| Other income, net | $1.8M | $776K | $1.1M | +138% |
| Net loss | $19.0M | $22.1M | −$3.1M | -14% |
| Costs & expenses | $20.9M | $22.9M | −$2.1M | -9% |
| Operating costs | $20.9M | $22.9M | −$2.1M | -9% |
| Research & development | $15.0M | $17.2M | −$2.3M | -13% |
| General & admin | $5.9M | $5.7M | $213K | +4% |
| Operating cash sources | $19.0M | $22.1M | −$3.1M | -14% |
| Depreciation | $27K | $30K | −$3K | -10% |
| Share-based compensation | $3.6M | $3.6M | −$12K | -0.3% |
| Working capital & other | $3.5M | −$800K | $4.3M | — |
| Cash used in operations | $11.9M | $19.4M | −$7.5M | -39% |
| Net loss absorbed | $19.0M | $22.1M | −$3.1M | -14% |
Questions
How much did Altimmune's revenue grow quarter over quarter in Q3 2025?
Altimmune's revenue rose $0 (0%) from $5K in Q2 2025 to $5K in Q3 2025.